drugset / Trial / NCT00101569
Aripiprazole Oral Acceptability Trial
Phase 3
Completed
59 enrolled
Otsuka Pharmaceutical Development & Commercialization, Inc.
Otsuka America Pharmaceutical · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this trial is to study liquid aripiprazole in patients with stable schizophrenia.
Timeline
- Start
- 2004-03
- Primary completion
- 2005-03
- Completion
- 2005-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aripiprazole | Other / unclassified | 15 mg | Oral |
| Subject | Aripiprazole | Other / unclassified | 15 ml | Oral |
| Subject | Aripiprazole | Other / unclassified | 30 mg | Oral |
| Subject | Aripiprazole | Other / unclassified | 30 ml | Oral |